Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780026 | 0.83 | LPL (0.31) | LPLLIPG | |
| SCHEMBL16042255 | 0.83 | LPL (0.31) | LPLLIPG | |
| SCHEMBL16042213 | 0.81 | LPL (0.35) | LPLLIPG | |
| SCHEMBL720902 | 0.81 | LPL (0.32) | LPLLIPG | |
| SCHEMBL16042106 | 0.78 | EGFR (0.37) | — | |
| SCHEMBL26674620 | 0.75 | LPL (0.38) | LPLLIPG | |
| SCHEMBL939408 | 0.73 | GPR3 (0.38) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1230718 | 0.72 | LPL (0.47) | LPLLIPG | |
| SCHEMBL30982000 | 0.72 | GAA (0.36) | LPLLIPG | |
| SCHEMBL27409909 | 0.72 | GAA (0.36) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786494-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10786494-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| CN-105960237-B | CCR6 compound | 凯莫森特里克斯股份有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-20190167659-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190167659-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| EP-3076968-B1 | CCR6 COMPOUNDS | CHEMOCENTRYX INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3076968-B1 | CCR6 COMPOUNDS | CHEMOCENTRYX INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10117865-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180092902-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180092902-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20160296508-A1 | CCR6 COMPUNDS | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| EP-3076968-A1 | CCR6 COMPOUNDS | ChemoCentryx, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9340509-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340509-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340509-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150175547-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175547-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175547-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2015-06-25 | — | — | US | disclosed |
| WO-2015084842-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015084842-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10117865-B2 | CCR6 compounds | CCR6, CCR1, CCR4 | CYP1A2 1609/4885CYP2C9 2916/4885CYP2C19 2941/4885 |
| US-20160296508-A1 | CCR6 COMPUNDS | CCR6, CCR1, CCR4 | CYP1A2 2229/4885CYP2C9 3771/4885CYP2C19 3985/4885 |
| US-20190167659-A1 | CCR6 COMPOUNDS | CCR6, CCR1, CCR4 | CYP1A2 1609/4885CYP2C9 2916/4885CYP2C19 2941/4885 |
| US-20180092902-A1 | CCR6 COMPOUNDS | CCR6, CCR1, CCR4 | CYP1A2 1609/4885CYP2C9 2916/4885CYP2C19 2941/4885 |
| US-20150175547-A1 | CCR6 COMPOUNDS | CCR6, CCR1, CCR4 | CYP1A2 1609/4885CYP2C9 2916/4885CYP2C19 2941/4885 |
| US-10786494-B2 | CCR6 compounds | CCR6, CCR1, CCR4 | CYP1A2 1609/4885CYP2C9 2916/4885CYP2C19 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.